Cryoport Q1 revenue falls 13% to $54.6M; net loss widens to $18.9M, adjusted EBITDA negative $7.7M

Cryoport, Inc.

2024-Q1 EPS reported -$0.43 revenue$54,592,000

Life Sciences Products revenue dropped 34% YoY to $17.8M, driven by slowdown in MVE cryogenic systems demand.
Life Sciences Services revenue rose 3% to $36.8M; BioStorage/BioServices up 9%.
Net loss attributable to common stockholders was $20.9M ($0.43 per share) vs $7.6M ($0.16) a year ago.
Full-year 2024 revenue guidance reaffirmed at $242-252M; CEO cites cost-reduction initiatives including workforce cuts.
Cryoport now supports 15 commercial cell & gene therapies; 675 global clinical trials as of March 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Cryoport, Inc. reported the first quarter ended March 31, 2024 results: revenue $54.6 million, net income $0.43 per share, EPS $0.43 per share. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $54.6 million
Net income: $0.43 per share
EPS: $0.43 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2413756d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-058082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.